Keywords: Rheumatoid arthritis, Market forecasts, Emerging oral agents, Pfizer, Takeda, AstraZeneca, Tofacitinib, Fostamatinib, Decision Resources
Rheumatoid arthritis drug market forecast to grow modestly to $15.2 billion in 2021
Article | 16 September 2012
The rheumatoid arthritis drug market will experience modest growth over the next decade as sales increase from $11.1 billion in 2011 to $15.2 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
